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ABSTRACT  
Objective:
Methods: A polymeric carrier was synthesized using tert-butyl methacrylate (TBMA) as a monomer, thioglycolic acid, and azobisisobutyronitrile as 
a radical polymerization initiator. The polymer was converted by acid hydrolysis into a water-soluble copolymer of TBMA and MAA of 20: 80 
mass%, respectively. The copolymer of TBMA and MAA was modified with 5-FU. Their formation was proved using IR and UV spectroscopy. The 
particle size of the 5-FU polymeric complex was estimated by turbidimetry, which is based on measuring the intensity of light transmitted through a 
disperse system. The release of 5-FU from the obtained ionic complexes by dialysis in vitro was evaluated.  
 The objective of this work was to obtain a water-soluble 5-fluorouracil (5-FU) polymeric complex on the basis of a methacrylic acid 
(MAA) copolymer to be used as an injectable chemotherapeutic agent.  
Results: Polymeric carriers were obtained with different amounts of 5-FU (5, 15, 25, 50 mol %). A high peak at λ = 266 nm was observed in the UV 
spectrum of the polymeric carrier (characteristic of 5-FU). The particle size was estimated at 13 nm for the complex with 5 mol% 5-FU and 26.8 n 
for the complex with 50 mol% 5-FU. The 5-FU release was estimated in two parallel experiments at 37 °C. One utilized a phosphate-citrate buffer 
with pH 5.0 to model the intracellular space and the other, a phosphate buffer with pH 7.4 to model the intravascular space. Two systems, with 5 
and 15 mol% 5-FU, were chosen for testing. In both phosphate buffer and phosphate-citrate buffer, 5-FU was released from the polymeric complex 
with 5 mol% 5-FU approximately 1.3 times faster than from the complex containing 5 mol% 5-fluorouracil. The kinetics of 5-FU release from the 
polymeric complex (5 mol% 5-fluorouracil) showed that the 5-FU release was 77.9% in phosphate-citrate buffer and 59.6% in phosphate buffer 
over 52 h of dialysis. When the 5-FU release kinetics was studied with the polymeric complex containing 15 mol% 5-FU, the 5-FU release was 
100.0% in phosphate-citrate buffer and 75.1% in phosphate buffer over 57 h of dialysis. 
Conclusion: Water-soluble nanoscale complexes of 5-FU with TBMA–MAA copolymers extend application of 5-FU, while its general toxicity might 
be lower. The complexes are sufficiently stable at pH 7.4 and readily release 5-FU at pH 5.0. 
Keywords: 5-fluorouracil, Water-soluble polymeric complex, Copolymer of t-butylmethacrylate, Methacrylic acid, Polymeric carrier 




5-Fluorouracil (5-FU) is a chemotherapeutic agent and is broadly 
used to treat oncology diseases. 5-FU is used to treat a variety of 
solid tumors [1, 2], including colorectal [3–5], breast [6], pancreatic 
[7], and gastric [8] cancers. 
  
Because 5-FU is metabolized rapidly, it is of immense importance to 
maintain its serum concentrations at high levels to improve the 
therapeutic efficacy. However, high risk of severe toxicity is involved 
in using 5-FU at high concentrations [9]. 
Systems for controlled release of 5-FU have been the focus of many 
studies described in the literature. Many of the systems are based on 
polypeptides and polysaccharides. Such systems are often capable of 
improving 5-FU treatment parameters [10]. 
Chitosan derivatives are commonly used as carriers [11]. Chitosan is 
biodegradable, biocompatible, inexpensive, minimally immunogenic, 
and low cytotoxic and has consequently found broad application 
[12]. Moreover, chitosan has functional groups that allow a simple 
binding of vectors and drugs. Yet its poor solubility limits its use as a 
carrier for drug delivery [13]. Water-soluble polymeric carriers are 
therefore necessary to design to achieve successful drug delivery.  
Polymethacrylates are a widely available class of polymers. 
Poly(methacrylic acid) (PMMA) and poly(acrylic acid) are water-
soluble polymers and have carboxylic functional groups to allow 
their modification. 
In 2016, a PMMA conjugate with gold nanoparticles and doxorubicin 
attached through an acid-labile cysteine bond was tested for 
anticancer properties in vitro and in vivo [14]. A high efficacy for 
both chemotherapy and radiation therapy was demonstrated for the 
conjugate in a human cervical adenocarcinoma cell line.  
A universal pH-sensitive nanoparticle system was proposed for 
selective drug delivery in 2011, using PMMA as a component [15]. 
Chitosan and PMMA were coated on mesoporous silica nanoparticles. 
Doxorubicin was used as a model drug to study nanoparticle behavior 
in conditions simulating those in biological media. The study showed 
that doxorubicin could be efficiently loaded into the resulting 
microspheres. The cumulative release was pH dependent. The 
doxorubicin release rate at low pH (5.5) was far faster than at pH 7.4. 
Cytotoxicity testing by the MTT assay showed that empty carrier 
microspheres were suitable as drug carriers. A similar system was 
described in 2014 [16]. A high encapsulating capacity for doxorubicin 
was demonstrated again for nanoparticles. The drug was readily 
released in response to a shift towards acidic pH (5.0). 
Poly (acrylic acid) is promising as a drug carrier because it is 
biocompatible and bioadhesive, the property being due to its 
carboxylic groups, which produce hydrogen bonds with mucin and 
glycoprotein on mucous membranes. Poly (acrylic acid) is 
temperature and pH sensitive. A new potential application of poly 
(acrylic acid) gels is delivering anticancer drugs in the 
gastrointestinal tract after their oral administration [17]. A 
polymeric system based on a chitosan–poly (acrylic acid) copolymer 
has been proposed for oral 5-FU delivery to treat colorectal cancer. 
The objective of this work was to obtain a water-soluble 5-FU 
polymeric complex on the basis of a methacrylic acid (MAA) 
copolymer to be used as an injectable chemotherapeutic agent.  
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MATERIALS AND METHODS 
Materials 
For synthesis of the polymer carrier, the following reagents were 
used: tert-butyl methacrylate (TBMA) as a monomer (98%, Aldrich); 
thioglycolic acid (TGA), azobisisobutyronitrile (AIBN) as a radical 
polymerization initiator. 5-fluorouracil (5-FU) was used for the 
preparation of the polymer complex. AIBN was purified by 
recrystallization from isopropyl alcohol and dried in a vacuum oven 
to constant weight. Reagents purchased from catalogs were not 
subjected to additional purification. TGA was purified by distillation 
in vacuo. Solvents, such as acetonitrile and tetrahydrofuran (THF), 
were purified by standard techniques [18]. 
Methods 
Polymerization of TBMA was carried out in bulk in the presence of 5·10-2 
M AIBN and TGA as a chain transfer agent at 70 °C. Initial reaction 
mixtures were added into dilatometric ampoules and degassed via three 
freezing–thawing cycles under vacuum; the ampoules were sealed then. 
The polymer was purified by triple precipitation from acetone with 
water and dried under vacuum to a constant weight. 
To estimate the molecular weight (MW) of a polymer, gel 
permeation chromatography (GPC) was run in tetrahydrofuran 
(TGF) at 40 °C, using polymethacrylate standards and a Prominence 
LC-20VP liquid chromatography system with two Styragel columns 
(pore sizes 106and 105Å) and a differential refractometer.  
PolyTBMA hydrolysis was carried out in dioxane supplemented with 
diluted HCl (1: 2), using 0.5 ml of the solution per 0.25 g of the 
polymer. The reaction was performed in a flask fitted with a reflux 
condenser at 60, 80, and 100°C. MAA units were quantified by 
potentiometric acid-base titration with 0.1 N KOH (a methanolic 
solution) in methanol.  
Generation of a polymeric complex with 5-FU 
A TBMA–MAA copolymer was dissolved in water and added to a 5-
FU solution in acetonitrile. The resulting mixture was incubated in 
the dark with continuous stirring on an electromagnetic stirrer for 
48 h. The solvent was removed, and the powder mixture was dried 
in an oven at 40 °C to a constant weight. 
UV spectra were recorded using a Shimadzu UV 1650 DC 
spectrometer (working range 190–1100 nm, wavelength accuracy 
0.3 nm). Substances to be tested were dissolved in water, a 
phosphate buffer (pH 7.4), and a phosphate–citrate buffer (pH 5.0) 
to 0.002 mg/5 ml. 
IR spectroscopy 
IR spectra of test substances were recorded using a FSM 1201 Fourier-
transform IR spectrometer (Monitoring, St. Petersburg, Russia) in a 
range of 400–4000 cm–1 (resolution 4 cm–1, number of scans 32, KBr 
windows). Samples were obtained as suspensions in mineral oil.  
Nuclear magnetic resonance (1H NMR) spectra were recorded 
using a Bruker FT-80 spectrometer. The spectrometer frequency 
was 400 MHz; the chemical shift 
The particle size of the 5-FU polymeric complex was estimated by 
turbidimetry, which is based on measuring the intensity of light 
transmitted through a disperse system. Polymeric complexes were used 
as 0.1% aqueous solutions. The optical density was measured using a 
photoelectric colorimeter with red and blue filters for each polymeric 
complex. The turbidity τ was calculated from Equation (1):  
δ was recorded against a 
tetramethylsilane internal standard. 
Estimation of the particle size for the 5-FU polymeric complex  
……… (1) 










 are the transmitted and incident light intensities, 
respectively; x is the sample path length; τ is the sample turbidity; 
and D is the optical density. The parameter k was then calculated 
from Equation (2): 
………. (2) 
Where λ is the wavelength, τ is the turbidity, and k is the wavelength 
exponent in Heller’s equation.  
Equation (3) was used to obtain the Z value corresponding to the 
given k:  
{ }kZ 87.0exp67 −= ………. (3) 
The particle size of the polymeric complex was calculated from 
Equation (4): 
………. (4) 


















 is the arithmetic mean 
wavelength used in the experiment. 
Estimation of the 5-FU release from the polymeric carrier in vitro  
The 5-FU release was measured in a buffer solution at pH 5.0 and 7.4. 
A polymeric complex was dissolved in the buffer solution to 1 mg/ml, 
and the resulting sample was added into a chamber of a dialysis cell. A 
buffer with the pH of interest was added into the other chamber. The 
chambers had a CelluSep T1 membrane (MW 3500 Da) between them. 
The cell was incubated in a thermostat at 37 °C. Aliquots (the total 
contents) were taken from the buffer chamber at certain time points to 
measure the free 5-FU content at 266 nm. 
RESULTS AND DISCUSSION  
Poly-TBMA (PTBMA) was chosen as a basis for 5-FU polymeric 
complexes because the polymer is simple to synthesize and then to 
hydrolyze to yield water-soluble TBMA–MAA copolymers or PMMA. 
TBMA was polymerized in the presence of AIBN (5·10-2 M) as a radical 
polymerization initiator and TGA as a chain transfer agent (Scheme 1). 
 
 
Scheme 1: The reaction of chain transfer to TGA in the course of 
TBMA radical polymerization 
 
As a chain transfer agent, TGA makes it possible to control both the 
MW and MW distribution (MWD) (table 1). 
 
Table 1: Effect of the TGA content (wt %) on the MW characteristics of PTBMA 
TGA content, wt% Mn M, Da w/Mn 
0 231 600 2.98 
0.5 18 000 1.95 
0.75 13 900 1.80 
1 12 400 1.35 
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When TGA was used as 1 wt%, conversion of ~98% was achieved in 
4 h and the resulting PTBMA had characteristics optimal for 
biocompatible polymers, that is, a low molecular weight and a low 

















= 1.35).  
Next, we studied the kinetics of PTBMA acid hydrolysis to obtain a 
biocompatible polymer with MAA units. As is seen from Scheme 2, 
PTBMA hydrolysis is autocatalytic and is irreversible because 
gaseous isobutylene is yielded. 
 
 
Scheme 2: Acid hydrolysis of PTBMA 
 
To estimate the activation energy of the process, experiments were 
performed at 60, 80, and 100 °C. An Arrhenius plot was constructed 
from the results and used to calculate the activation energy of acid 
hydrolysis of PTBMA; Еа  = 9.34 kJ/mol. The low Еа  value suggests a 
high rate for acid hydrolysis of PTBMA, providing optimal conditions 
for generating a polymer with necessary properties. 
An 80% conversion was achieved when PTBMA was hydrolyzed at 
100 °C for 12 h; i.e., a TBMA–MAA copolymer with a component 
proportion of 20: 80 wt% was obtained (Scheme 3). 
The process was verified by NMR spectroscopy (fig. 1). A new peak 
at 12.28 ppm, suggesting generation of carboxyl groups, became 
detectable in the sample after hydrolysis. 
 




Fig. 1: Fragment of the 1H-NMR spectrum obtained for a PTBMA 
sample after its hydrolysis 
 
Complexes of 5-FU with the TBMA–MAA copolymer were obtained 
at the next step of the study (table 2). 
 
Table 2: 5-FU content (mol %) in polymeric complexes with TBMA–MAA 
Polymeric carrier 5-FU loading amount (mol%) 
 
TBMA–MAA (80 wt%), Mn  = 12 400, Mw/Mn
5 





















Fig. 2: Intermolecular interaction between 5-FU and a MAA 
carboxyl group of the TBMA–MAA copolymer. R is the TBMA–
MAA copolymer moiety 
 
Intermolecular interactions between 5-FU and carboxyl groups of 
MAA residues of the copolymer (Scheme 3) yielded a water-soluble 
polymeric complex (fig. 2-4). 
The intermolecular interaction includes a hydrogen bonding of the 
electronegative fluorine atom of 5-FU and the hydrogen atom that 
carries a partial positive charge and is covalently bound with the 
electronegative oxygen atom in the MAA carboxyl group. Additional 
hydrogen bonds arise between the hydrogen of the–NH group of the 
pyrimidine ring and an oxygen of the MAA residue and between 
oxygen and hydrogen atoms in the MAA residue. The mechanism 
indicates that 5-FU is fully complementary to the MAA residue. A 5-
FU molecule binds fully two MAA residues and, partly, a third MAA 
residue. 
The formation of an intermolecular complex between 5-FU and the 
TBMA–MAA copolymer was confirmed by IR and UV spectroscopy 
data (table 3). 
The results of IR spectroscopy are consistent with the results of 
other researchers. The C = O of polymer closes by bands from C=O of 
5-FU, but we see bands of OH from COOH in the IR-spectrum. The 
C=O stretching vibrations of heterocyclic imide and amide groups 
are observed at 1725 and 1673 cm−1, respectively. N–H bending is 
observed at 1504 cm−1
A high peak at λ = 266 nm was observed in the UV spectrum of the 
polymeric complex. The peak was characteristic of 5-FU and absent 
from the spectrum of the TBMA–MAA copolymer (fig. 3). 
 [21, 22].  
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Table 3: IR spectrum peaks of 5-FU, TBMA–MAA copolymer and ionic complex of TBMA–MAA copolymer and 5-FU 
IR spectrum peaks TBMA–MAA copolymer 5-FU Ionic complex of TBMA–MAA copolymer 
and 5-FU 
Broad peak at 3500–3000 cm
 
–1 ОН (carboxyl group)              - ОН (carboxyl group) 
1725 cm−1,  1673 cm  −1 C=O stretching vibrations of heterocyclic imide and amide groups 
1580 – 1520 cm - –1 Fluctuations of the ring 
1504 cm - –1  N-H Bending 
Vibrations 
Valence fluctuations 
of the ring 
- 
1247 cm - –1 C-F[19] 
880 cm  –1 Fluctuations of the ring[20]   
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Fig. 3: UV spectra of 5-FU (2·10–8g/ml, a 100-fold dilution), the TBMA–MAA copolymer (20: 80 wt%, 4·10–7 g/ml), and the TBMA–MAA 
complex with 5-FU (4·10–7
 
The particle size was estimated at 13 nm for the complex with 5 mol 
% 5-FU and 26.8 n for the complex with 50 mol% 5-FU. 
The 5-FU release was estimated in two parallel experiments at 37 °C. 
One utilized a phosphate-citrate buffer (PCB) with pH 5.0 to model 
the intracellular space and the other, a phosphate buffer (PB) with 
pH 7.4 to model the intravascular space. Two systems, with 5 and 15 
mol% 5-FU, were chosen for testing (fig. 2, 3). 
 g/ml) 
In both PB and PCB, 5-FU was released from the polymeric complex 
with 5 mol% 5-FU approximately 1.3 times faster than from the 
complex containing 5 mol% 5-FU.  
The kinetics of 5-FU release from the polymeric complex with 
TBMA–MAA (5 mol% 5-FU) showed that the 5-FU release was 77.9% 
























Fig. 4: Release of 5-FU from its polymeric complex with TBMA–MAA (5 mol% 5-FU) 
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Fig. 5: Release of 5-FU from its polymeric complex with TBMA–MAA (15 mol% 5-FU) 
 
When the 5-FU release kinetics was studied with the TBMA–MAA 
polymeric complex containing 15 mol% 5-FU, the 5-FU release was 
100.0% in PCB and 75.1% in PB over 57 h of dialysis (fig. 5). 
CONCLUSION 
Water-soluble nanoscale complexes of 5-FU with TBMA–MAA 
copolymers extend application of 5-FU, while its general toxicity 
might be lower. The complexes are sufficiently stable at pH 7.4 and 
readily release 5-FU at pH 5.0. We have proposed the 5-FU polymer 
system as the basis for an injection pharmaceutical composition. The 
formation of the polymer complex in 5-fluorouracil. It is confirmed 
by IR spectroscopy and is consistent with the results of other 
researchers [21, 22]. A large amount of research directed to polymer 
systems 5-FU for oral administration. Currently, creation of 
polymeric derivatives of antitumor drugs is a promising direction of 
development of new pharmaceutical compositions [23-27]. These 
polymeric systems can alter the pharmacokinetics and increase the 
focus of the drug, while reducing the toxic effects on the body. 
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